Replimune's top three insider shareholders as of June 10, 2026 are Fund Iv, L.P. Omega (TenPercentOwner, 9.44Mn shares), Robert Coffin (President Chief Rd Officer, 1.82Mn shares), Philip Astley-Sparke (Director, 1.43Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Philip Astley-Sparke | - | 1,430,071 | 0 | 07 Apr, 2026 |
| Robert Coffin | President Chief Rd Officer | 1,821,872 | 0 | 20 May, 2024 |
| Colin Love | Chief Operating Officer | 777,345 | 0 | 20 May, 2024 |
| Tanya Lewis | Chief Dev. Op. Officer | 135,293 | 0 | 15 Jun, 2023 |
| Fund Iv, L.P. Omega | - | 4,673,380 | 4,763,380 | 16 Mar, 2022 |
| Jean M. Franchi | Chief Financial Officer | 128,748 | 0 | 18 May, 2023 |
| Pamela Esposito | Chief Business Officer | 263,436 | 0 | 13 Sep, 2023 |
| Emily Luisa Hill | Chief Financial Officer | 194,368 | 0 | 19 Dec, 2025 |
| Sushil Patel | Chief Executive Officer | 784,816 | 0 | 07 Apr, 2026 |
| Konstantinos Xynos | Chief Medical Officer | 249,685 | 0 | 07 Apr, 2026 |
| Andrew Schwendenman | Chief Accounting Officer | 114,951 | 0 | 07 Apr, 2026 |
| Christopher Sarchi | Chief Commercial Officer | 151,588 | 0 | 06 Apr, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 01 Apr, 2026 | Veleka Peeples-Dyer | Stock Option (right to buy) | A | 44,500 | $0.00 | 44,500 | D | A |
| 01 Apr, 2026 | Andrew Schwendenman | Common Stock | D | 36,667 | $0.00 | 114,951 | D | A |
| 01 Apr, 2026 | Konstantinos Xynos | Common Stock | A | 50,000 | $0.00 | 249,685 | D | A |
| 01 Apr, 2026 | Andrew Schwendenman | Common Stock | D | 36,667 | $0.00 | 114,951 | D | A |
| 01 Apr, 2026 | Konstantinos Xynos | Common Stock | A | 50,000 | $0.00 | 249,685 | D | A |
| 01 Apr, 2026 | Paolo Pucci | Stock Option (right to buy) | A | 44,500 | $0.00 | 44,500 | D | A |
| 01 Apr, 2026 | Kapil Dhingra | Stock Option (right to buy) | A | 44,500 | $0.00 | 44,500 | D | A |
| 01 Apr, 2026 | Dieter Weinand | Stock Option (right to buy) | A | 44,500 | $0.00 | 44,500 | D | A |
| 01 Apr, 2026 | Philip Astley-Sparke | Common Stock | A | 50,000 | $0.00 | 1,430,071 | D | A |
| 01 Apr, 2026 | Sushil Patel | Common Stock | A | 251,240 | $0.00 | 784,816 | D | A |
| 01 Apr, 2026 | Christopher Sarchi | Common Stock | A | 50,000 | $0.00 | 201,588 | D | A |
| 01 Apr, 2026 | Christy J. Oliger | Stock Option (right to buy) | A | 44,500 | $0.00 | 44,500 | D | A |
| 01 Apr, 2026 | Konstantinos Xynos | Employee Stock Option (right to buy) | A | 75,000 | $0.00 | 75,000 | D | A |
| 01 Apr, 2026 | Sushil Patel | Employee Stock Option (right to buy) | A | 376,860 | $0.00 | 376,860 | D | A |
| 01 Apr, 2026 | Andrew Schwendenman | Employee Stock Option (right to buy) | A | 55,000 | $0.00 | 55,000 | D | A |
| 01 Apr, 2026 | Konstantinos Xynos | Employee Stock Option (right to buy) | A | 75,000 | $0.00 | 75,000 | D | A |
| 01 Apr, 2026 | Philip Astley-Sparke | Stock Option (right to buy) | A | 75,000 | $0.00 | 75,000 | D | A |
| 01 Apr, 2026 | Andrew Schwendenman | Employee Stock Option (right to buy) | A | 55,000 | $0.00 | 55,000 | D | A |
| 01 Apr, 2026 | Christopher Sarchi | Employee Stock Option (right to buy) | A | 75,000 | $0.00 | 75,000 | D | A |
| 02 Apr, 2026 | Christopher Sarchi | Common Stock | D | 6,500 | $8.01 | 151,588 | D | S |